Matthews International reports Q2 2026 results today with bears firmly entrenched — yet the borrow market tells a more measured story than the headline short interest figure implies.
Short sellers hold 7.7% of the free float — a meaningful position, and one that has barely moved over the past month, edging up just 1.3%. The ORTEX short score of 66 confirms sustained short-side pressure. Days to cover has stretched to 25.9 — one of the most elevated readings in the broader universe, ranking in the 2nd percentile on DTC — meaning shorts face a long runway to exit if the print surprises. Yet the borrow itself remains cheap and comfortable: cost to borrow is running near 0.54%, barely changed over the past month, and availability is relaxed enough that new short positions carry no real squeeze risk heading into the event.
The options market adds nuance. The put/call ratio of 2.29 sounds alarming in isolation, but it is actually fractionally below its 20-day average of 2.31 — a z-score of -0.67. That means options positioning is essentially neutral relative to recent history, despite the structurally high ratio that reflects thin activity in this name. There is no fresh options-driven panic signal here.
The bull case for Matthews rests on recovery potential and a compelling valuation setup. At an EV/EBITDA of roughly 9.3x on estimated revenues near $1.1 billion, the stock trades at a modest multiple for an industrial with two distinct business lines — memorialization products and industrial technologies. The EPS surprise factor score ranks in the 100th percentile, meaning the company has consistently outrun estimates. That track record matters ahead of a print where the consensus carry-into is already cautious. The most recent confirmed analyst data is stale — B. Riley Securities last updated its target to $40 in September 2024, against a current price of $28.54 — and no fresh analyst moves appear in the recent record, so the debate is largely between what the numbers deliver rather than what the Street expects. The bear thesis is simpler: net debt of $441 million, interest expense of $46 million, and the operational complexity of managing both death-care products and packaging technologies under the same roof.
Price action has been the one genuinely bullish data point in the setup. The stock has recovered 13.4% over the past month to close at $28.54, adding 2.7% in the final session before today's report. The two prior earnings reactions in the data — a 1.8% one-day gain in February 2026 and a 0.8% gain following the November 2025 release — show a pattern of modest but positive initial responses. The print will test whether that recovery has legs, or whether 7.7% short interest and $441 million in net debt are the story that reasserts itself once the numbers are in.
See the live data behind this article on ORTEX.
Open MATW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
